Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


|About: Generex Biotechnology Corp. (GNBT), GNBT

  • Upfront license payments for AE37 by Shenzhen BioScien Pharmaceuticals for Prostate Cancer in China, Taiwan, Hong Kong and Macau.
  • Plans underway for the spin-out of NuGenerex Immuno-Oncology that includes A37.
  • Proprietary buccal oral insulin delivery for $27 billion insulin market.
  • LOI to acquire majority interest in ALTuCELL and their Cellular Therapy Product Altsulin® with Patented Microencapsulation Technology for the Treatment of Type I Diabetes.
  • FDA approved Advanced Wound Care products.
  • Broad product line of FDA approved orthopedic implants.
  • Aggressive acquisition strategy building Generex rapidly.
  • 9-month 2019 revenues increased 2,800 times versus same 2018 period.
  • Upcoming 1 for 1 dividend ONLY to float shareholders.
  • Recently retired 20,375,900 shares
  • Upcoming Nasdaq up-list announced.


Generex Biotechnology Corp. (GNBT: OTC) shares have been in a strong uptrend and steadily climbing during the short time since Joe Moscoto took over the helm of the company. Since then, the company has amassed an almost unbelievable number of acquisitions and LOI’s where each one has multi-blockbuster potential to transform Generex from a minnow into a whale. Revenues are already showing substantial gains with 9 month ending April 30, 2019 reported at $6,217,039 versus $2,218 for the same period in 2018. With expected high growth from the accumulated earning of all divisions, it would not be surprising to see shares trade over $12 in the next 12 months and there is also the potential for soaring prices if the news is good on A37 and the new diabetes delivery system and the new treatment for Type 1 diabetes and other indications.

Generex Biotechnology - GNBT - 1 year chart

In addition to large revenue growth expectations, the company has announced a spin-out of the NuGenerex Immuno-Oncologythat owns the rights to the exciting new cancer treatment drug, A37, a 1 for 1 share dividend pay able only to float shareholders, the retirement of over 20 million shares, and an impending up-listing to NASDAQ.

With breakthrough products that are either already approved for sale by regulatory agency or in the pipeline for approvals, Generex is strongly positioned to enjoy extraordinary financial performance in the not too distant future.

With a market cap of well under $200 million, Generex shares appear very undervalued.

The following recent press release tells more of their exciting story:

Generex Biotechnology Announces First Patient Enrolled in the Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (KeytrudaÒ) for the Treatment of Triple Negative Breast Cancer

MIRAMAR, Fla., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( (GNBT) ( today announced that the NSABP Foundation, Inc. (NSABP) has enrolled the first patient in the study: A Phase II Clinical Trial ofPembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple Negative Breast Cancer (NSABP FB-14). The trial, conducted in conjunction with research partners Merck and the NSABP Foundation, is designed to evaluate the safety and tolerability of AE37 given in combination with KEYTRUDAÒ (pembrolizumab) as well as the objective response rate.

Eric von Hofe, President of NuGenerex-ImmunoOncology commented, “This is an exciting milestone for NuGenerex Immuno-Oncology, as we have now revitalized our AE37 development program with a focus on combination therapy with checkpoint inhibitors, which are now becoming standard of care for a broad array of cancers. Combining our promising immunotherapeutic with Merck’s checkpoint inhibitor, KEYTRUDA for the treatment of triple negative breast cancer represents a novel treatment strategy for a cancer of high unmet need. Prior studies with each agent alone showed promising signs of efficacy. By combining the mechanisms of checkpoint inhibition by KEYTRUDA with the robust, long-lasting and tumor-specific T-cell activation by AE37, we hope to enhance the clinical effectiveness of the immunotherapy strategies.”

Jason Terrell, MD, Chief Scientific and Medical Officer of Generex Biotechnology commented, “The start of patient enrollment represents the culmination of a committed effort by the team at NuGenerex Immuno-Oncology (formerly Antigen Express) and our research partners at the NSABP Foundation and Merck. NuGenerex Immuno-Oncology has been a pioneer on the forefront of immunotherapy for over a decade with our Ii-Key platform that ensures CD4 T-cell activation against any tumor antigen to which the Ii-Key is attached. The Ii-Key platform holds great promise, and we plan to initiate additional trials using the combination of checkpoint inhibitors with AE37 immune system activation in the field of personalized immuno-oncology to help patients in need of treatment options.”

About Generex Biotechnology Corp.Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.

Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.

About Olaregen TherapeuticxOlaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. Generex aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care. Olaregen's first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications. Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets. Additionally, Excellagen can serve as an Enabling Delivery Platform for pluripotent stem cells, antimicrobial agents, small molecule drugs, DNA-Based Biologics, conditioned cell media and peptides. Olaregen's initial focus will be in advanced wound care including diabetic foot ulcers (DFU), venous leg ulcers and pressure ulcers. Future products focusing on innovative therapies in bone and joint regeneration comprise the current pipeline. Generex's mission is to become a significant force in regenerative medicine and advance the science of healing.

About Service-Disabled Veteran-Owned Small Business (SDVOSB)This a Service-Disabled Veteran-Owned Small Business (SDVOSB) that specializes in the sale, marketing, and distribution of innovative medical products through a nationwide network of veteran owned distribution services.

About Pantheon MedicalPantheon Medical is a manufacturer of a physician friendly, “all-in-one”, integrated kit that includes plates, screws, and tools required for orthopedic surgeons and podiatrists conducting foot and ankle surgeries. Generex is developing and submitting several new product lines to the FDA which will include cannulated surgical screws, plates, and implants.

About MediSource PartnersMediSource Partners is a 10-year-old private company, currently contracted with over 25 vendors (including Pantheon Medical) for nationwide distribution of implants and devices for spine, hips, knees, foot, ankle, hand, and wrist surgeries. Additional product lines include biologics (blood, bone, tissue, stem cells), durable medical equipment, and soft goods. Generex also supplies kits to process bone marrow aspirates and platelet rich plasma biologics at the time of surgery.


Generex Biotechnology appears strongly positioned to enjoy substantially higher price multiples of today’s $2.70 per share. GNBT share price has been continually rising as the company is positioning for several major achievements in 2019 and beyond. There are risks associated with all drug development, but navigating any drug through the challenging FDA approval, can create remarkably high valuations and share prices. Generex offers the additional advantage of diversification of potentially large revenues from several different profit centers other than drug development. Generex Biotechnology is showing early signs of very strong revenue reversal and of being the new rising star of biotech. Generex warrants a close look and early positioning before revenues and developments advance further. An interesting note is that small investors have the advantage of being able to purchase shares now while larger institutional investors typically cannot buy any shares that are under $5.00.

Legal Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging MicroCaps or BioResearchAlert or its principals may have been compensated for its services in the form of cash-based compensation. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as ''expects,'' ''will,'' ''anticipates,'' and ''estimates''; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.